Department of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
J Control Release. 2012 Dec 10;164(2):177-82. doi: 10.1016/j.jconrel.2012.07.045. Epub 2012 Aug 18.
Advances in nanotechnology for oncology will arise from an increased understanding of the interaction between nanomaterials and biological systems; refinement of multifunctional nanocomposites for applications such as simultaneous imaging and therapy (theranostics); and harnessing of the unique physicochemical properties arising from nanoscale effects which distinguish them from small-molecular-weight molecules in the detection and destruction of cancer cells with high selectivity and efficiency. The major challenges in successful clinical translation of tumor specific nanoparticle delivery include overcoming various biological barriers and demonstrating enhanced therapeutic efficacy over the current standard of care in the clinic. For many nanoparticle mediated theranostic applications, image guidance can play a crucial role not only in exploiting the cancer specific imaging capabilities of these novel particles, but in planning, targeting, monitoring and verifying treatment delivery, thus enhancing the safety and efficacy of these emerging procedures.
肿瘤纳米技术的进展将源于对纳米材料与生物系统相互作用的深入了解;改进多功能纳米复合材料,以实现如同时成像和治疗(治疗诊断学)等应用;利用源于纳米级效应的独特物理化学特性,将其与小分子药物区分开来,从而以高选择性和高效率检测和破坏癌细胞。成功将肿瘤特异性纳米颗粒递送至临床应用的主要挑战包括克服各种生物学障碍,并在临床治疗中展示优于当前标准护理的增强治疗效果。对于许多基于纳米颗粒的治疗诊断应用,图像引导不仅可以发挥重要作用,不仅可以利用这些新型粒子的肿瘤特异性成像能力,而且可以在规划、靶向、监测和验证治疗输送方面发挥作用,从而提高这些新兴治疗方法的安全性和有效性。